Literature DB >> 33830351

Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.

Kazumitsu Aoki1,2, Satoru Matsunaga1,3, Shinichirou Ito4, Takahiko Shibahara4, Takeshi Nomura3,5, Hideo Matsuzaki2, Shinichi Abe1,3, Akira Yamaguchi6,7.   

Abstract

BACKGROUND: Bisphosphonate and denosumab are widely used for the treatment of osteoporosis and bone metastasis of cancer to prevent excessive bone resorption. Osteonecrosis of the jaw is a serious adverse effect of bisphosphonate or denosumab referred to as bisphosphonate-related osteonecrosis of the jaw (BRONJ) or denosumab-related osteonecrosis of the jaw (DRONJ), respectively. Since bisphosphonate and denosumab inhibit bone resorption by different mechanism, we evaluated whether these drug types result in different histopathological characteristics related to bone resorption.
MATERIALS AND METHODS: We histopathologically investigated 10 cases of BRONJ, DRONJ, and suppurative osteomyelitis. Paraffin sections prepared from decalcified dissected jaw bones were used for histopathological observation, second harmonic generation imaging, and bone histomorphometry. The samples were also observed by a scanning electron microscope.
RESULTS: Numerous bone resorption lacunae were observed on the necrotic bone surface in almost all cases of BRONJ; however, such resorption lacunae were limited in DRONJ and suppurative osteomyelitis. Prominent bone resorption lacunae were also confirmed by second harmonic generation imaging and scanning electron microscopy in BRONJ, but not in DRONJ or suppurative osteomyelitis. As determined by bone histomorphometry, the number of bone resorption lacunae and the length of the erosion surface of resorption lacunae were significantly higher in BRONJ group than in the DRONJ and suppurative osteomyelitis groups. These parameters were correlated between the necrotic bones and the vital bones in BRONJ.
CONCLUSIONS: Persistent bone resorption lacunae on the necrotic bone surface are unique to BRONJ, providing a basis for distinguishing BRONJ from DRONJ and OM in histopathological diagnosis.

Entities:  

Keywords:  BRONJ; Bisphosphonate; Bone resorption lacunae; Denosumab; Osteonecrosis of jaw

Year:  2021        PMID: 33830351     DOI: 10.1007/s00774-021-01223-4

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  2 in total

1.  Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.

Authors:  Masanori Nashi; Toshinori Hirai; Takuya Iwamoto; Toshihiko Takenobu
Journal:  J Bone Miner Metab       Date:  2022-09-27       Impact factor: 2.976

Review 2.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.